Quick Answer
Sionna Therapeutics, Inc. reported Cash and Equivalents of $58.45 million for fiscal year 2025.
Sionna Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $58.45M | +54.7% |
| 2024 | $37.79M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $50.83M | +42.2% | +24.0% |
| June 30, 2025 | $40.98M | -6.9% | -50.4% |
| March 31, 2025 | $82.69M | -0.1% | +118.8% |
| December 31, 2024 | $37.79M | — | +5.7% |
| September 30, 2024 | $35.75M | — | -18.8% |
| June 30, 2024 | $44.02M | — | -46.8% |
| March 31, 2024 | $82.75M | — | — |
- Sionna Therapeutics, Inc. showed an increase of +54.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2024–2025 period, Sionna Therapeutics, Inc.’s cash and equivalents has grown by 54.7% (from $37.79 million to $58.45 million).
- The most recent figure is from Sionna Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: